Related references
Note: Only part of the references are listed.Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
Giusy Gentilcore et al.
BMC CANCER (2013)
BRAF inhibitor activity in V600R metastatic melanoma
Oliver Klein et al.
EUROPEAN JOURNAL OF CANCER (2013)
Effect of vemurafenib on a V600R melanoma brain metastasis
Rob R. H. van den Brom et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations
Giovanni Ponti et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Lu Si et al.
EUROPEAN JOURNAL OF CANCER (2012)
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
Giovanni Ponti et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
Christine M. Lovly et al.
PLOS ONE (2012)
BRAFV600E detection in melanoma is highly improved by COLD-PCR
Pamela Pinzani et al.
CLINICA CHIMICA ACTA (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mutation-driven drug development in melanoma
Keith T. Flaherty et al.
CURRENT OPINION IN ONCOLOGY (2010)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Jill C. Rubinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma
Cynthia Spittle et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Determinants of BRAF mutations in primary melanomas
JL Maldonado et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
